TELA Bio, Inc. (TELA)
NASDAQ: TELA · Real-Time Price · USD
0.9327
-0.0873 (-8.56%)
At close: Jan 20, 2026, 4:00 PM EST
0.9328
+0.0001 (0.01%)
Pre-market: Jan 21, 2026, 4:07 AM EST
TELA Bio Revenue
TELA Bio had revenue of $20.69M in the quarter ending September 30, 2025, with 9.14% growth. This brings the company's revenue in the last twelve months to $77.06M, up 12.24% year-over-year. In the year 2024, TELA Bio had annual revenue of $69.30M with 18.56% growth.
Revenue (ttm)
$77.06M
Revenue Growth
+12.24%
P/S Ratio
0.53
Revenue / Employee
$368,684
Employees
209
Market Cap
41.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69.30M | 10.85M | 18.56% |
| Dec 31, 2023 | 58.45M | 17.04M | 41.13% |
| Dec 31, 2022 | 41.42M | 11.96M | 40.58% |
| Dec 31, 2021 | 29.46M | 11.25M | 61.77% |
| Dec 31, 2020 | 18.21M | 2.77M | 17.91% |
| Dec 31, 2019 | 15.45M | 7.17M | 86.68% |
| Dec 31, 2018 | 8.27M | 4.03M | 94.91% |
| Dec 31, 2017 | 4.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myomo | 41.64M |
| Cytosorbents | 36.98M |
| Baird Medical Investment Holdings | 31.86M |
| electroCore | 29.84M |
| Spectral AI | 23.17M |
| Elutia | 21.75M |
| NeuroOne Medical Technologies | 12.10M |
| IceCure Medical | 2.98M |
TELA News
- 5 weeks ago - TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - These Analysts Cut Their Forecasts On TELA Bio After Q3 Earnings - Benzinga
- 2 months ago - TELA Bio, Inc. (TELA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility - GlobeNewsWire
- 3 months ago - TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran - GlobeNewsWire
- 5 months ago - TELA Bio, Inc. (TELA) Q2 2025 Earnings Call Transcript - Seeking Alpha